Blood-based monitoring identifies acquired and targetable driver

Plasma genotyping identifies potentially actionable mutations at variable mutant allele frequencies, often admixed with multiple subclonal variants, highlighting the need for their clinical and functional validation. We prospectively monitored plasma genotypes in 143 women with endocrine-resistant metastatic breast cancer (MBC), identifying multiple novel mutations including

Déclaration de conflit d'intérêts

Competing interestsMGH has filed for patent protection for the CTC-iChip technology. D.J. has served as a Consultant/Advisory Board at Novartis, Genentech, Eisai, Ipsen, and EMD Serono. L.S. has served as a Consultant/Advisory Board at Novartis. S.I. has served as a Consultant/Advisory Board at Abbvie, PharaMar, Genentech/Roche, Myriad Genetics, Hengrui Therapeutics, Puma Biotech, and Immunomedics. B.M. spouse has served as a Consultant/Advisory Board at MOTUS GI. A.J.I has served as a Consultant/Advisory Board at Roche, Chugai, Constellation, and Pfizer, and has ownership interests and intellectual property rights/inventor/patent holder at ArcherDx. A.B. has served as a Consultant/Advisory Board at Novartis, Pfizer, Genentech/Roche, Radius Health, Merck, Spectrum pharma, Immunomedics, Sanofi, Daiichi Pharma, and Taiho Oncology, and has research Grant from Biothernostics (self), Genentech (institution), Novartis (institution), Pfizer (institution), Merck (institution), Sanofi (institution), Radius Health (institution), Immunomedics (institution), Mersana(institution), and Innocrin (institution). All other authors declare no competing interests.